| IDXX |
Report |
Revenue |
IN-LINE |
pred ~$1.205B vs. cons $1.198B |
MEDIUM |
| IDXX |
Report |
Operating diluted EPS |
IN-LINE |
pred ~$3.96 vs. cons $3.92 |
MEDIUM |
| IDXX |
Report |
CAG diagnostics recurring revenue |
IN-LINE |
pred ~$966M vs. cons $962.9M |
MEDIUM |
| IDXX |
Guide |
FY26 revenue |
UNCHANGED |
guide $4.675B-$4.760B vs. cons $4.705B |
MEDIUM |
| IDXX |
Guide |
FY26 operating EPS |
UNCHANGED |
guide $14.45-$14.90 vs. cons $14.66 |
MEDIUM |
| IDXX |
Guide |
Q3 revenue |
UNCHANGED |
guide midpoint ~$1.20B vs. cons $1.191B |
LOW |
| IDXX |
Guide |
Q3 operating EPS |
UNCHANGED |
guide midpoint ~$3.76 vs. cons $3.76 |
LOW |
| IDXX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| IDXX |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY outlook leaves estimates flat and exposes the premium multiple |
LOW |